SCA
IPXL

Strategic Capital Alternatives’s Impax Laboratories, Inc. IPXL Stock Holding History

Strategic Capital Alternatives’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-468
Closed -$22K – 521
2015
Q2 		$22K Hold
468
– – 0.01% 372
2015
Q1 		$22K Buy
+468
New +$18.6K 0.01% 272

Other funds holding IPXL

HP
Hound Partners New York $863M AUM 11.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Strategic Capital Alternatives's IPXL Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of Impax Laboratories, Inc. (IPXL) in Q3 2015, closing a stake of 468 shares — an estimated $22K sold.

Strategic Capital Alternatives first reported a position in IPXL in Q1 2015 and held it in 2 quarters. The position peaked at $22K in Q2 2015. 195 funds tracked by Wall St. Rank hold IPXL as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining Impax Laboratories, Inc. position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 468 Impax Laboratories, Inc. shares in Q3 2015, an estimated $22K.
  • Strategic Capital Alternatives first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 2 quarters.
  • Strategic Capital Alternatives's Impax Laboratories, Inc. position peaked at $22K in Q2 2015.
  • 195 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.